Here's why the Creso Pharma (ASX:CPH) share price is up 7%

Good news out of the Creso Pharma camp this morning.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price has climbed well into the green in early trade today.

Cresco Pharma shares are now exchanging hands at 11.75 cents apiece, an almost 7% gain from the open.

What is Creso Pharma?

Creso Pharma develops and commercialises pharmaceutical cannabis and psychedelic compounds to treat health and medical conditions.

The company has a wide footprint across Switzerland, Australia, Canada, Colombia and Israel, but realises most revenue from Europe and the Middle East.

Creso Pharma has a market capitalisation of $131 million at the time of writing.

What's behind today's gains?

Creso provided an update on "operational progress" achieved through its Canadian subsidiary, Halucenex Life Sciences.

Halucenex is a research company focused on developing novel psychedelic compounds. These products are then sold to the pharmaceutical markets.

Creso announced that Halucenex has completed all satisfactory requirements for USP 61 microbial enumeration testing.

This is a significant milestone that demonstrates Creso's psilocybin compound is of pharmaceutical grade and safe from microbial nasties.

Furthermore, the company announced it had "commenced USP 62 protocols".

That is a similar test that examines pharmaceutical products for the presence of additional pathogens and other microbes.

It is an essential phase of any route to market in the pharmaceutical industry because the product must be deemed fit for humans.

Creso seems confident the test will "deem the company's products safe for human consumption" if successful.

What else does this mean?

Moreover, if successful, it will progress Halucenex's clinical trial authorisation (CTA) with Health Canada, helping to move forward its clinical trial pipeline.

Receiving the CTA allows the company to commence its phase II efficacy trial investigating the use of psilocybin in the treatment of post-traumatic stress disorder (PTSD).

Creso estimates the PTSD therapeutics market is worth "upwards of US$10.5 billion by 2025" and the company intends to "grow its market share across the sector" in the coming periods.

Market sentiment around clinical trial progress is a major force that drives share price returns in biotech and biopharma companies. That means good news is reflected on the charts for these shares.

In addition, Creso also released its quarterly update on Monday which shot its share price 9% higher on the day.

It stands to reason these two factors are behind the movement in the Creso Pharma share price today.

Creso Pharma share price snapshot

The Creso Pharma share price has posted a loss of 35% since January 1 this year. Over the last month, Creso shares have dipped 13% into the red.

Despite this, Creso shares have still climbed 279% into the green over the past 12 months.

This has outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of around 26% over the past year.

Contributor Zach Bristow has no position on any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Emotional euphoric young woman giving high five to male partner, celebrating family achievement, getting bank loan approval, or financial or investing success.
Share Gainers

Why Bowen Coal, Droneshield, Mesoblast, and St Barbara shares are racing higher today

These shares are ending the week positively. But why?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Avita Medical, GenusPlus, Mesoblast, and Polynovo shares are storming higher

These shares are having a better day than most today. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why EOS, News Corp, Polynovo, and Pro Medicus shares are roaring higher today

These shares are starting the week positively. But why?

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Share Gainers

5 ASX 200 stocks marching higher this week even as the market sinks

These five ASX 200 companies are shrugging off the broader selling to march higher this week.

Read more »

Rising share price chart.
Share Gainers

Why Novonix, HMC, Karoon Energy, and Ventia shares are pushing higher

These shares are ending the week on a positive note. But why?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Share Gainers

3 top ASX 200 stocks I wish I'd owned in 2024

These three top ASX 200 stocks are racing higher in 2024.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Champion Iron, EBR Systems, Mesoblast, and Patriot Battery Metals shares are surging today

These shares are avoiding the market selloff on Thursday. But why?

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors ended up snatching defeat from the jaws of victory today.

Read more »